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Commencement of antiretroviral treatment (ART) in severely immunosuppressed HIV-infected persons is associated with
unmasking of subclinical disease. The subset of patients that are diagnosed with tuberculosis (TB) disease while on ART have
been classiﬁed as ART-associated TB. Few studies have reported the incidence of ART-associated TB and unmasking TB-IRIS
according to the International Network for the Study of HIV-Associated IRIS (INSHI) consensus deﬁnition. To determine the
incidence and predictors of ART-associated TB, we screened 219 patients commencing ART at the Infectious Diseases Clinic in
Kampala, Uganda for TB by symptoms, sputum microscopy, and chest X-rays and followed them for one year. Fourteen (6.4%)
patients were diagnosed with TB during followup. Eight (3.8%) patients had ART-associated TB (incidence rate of 4.3 per 100
person years); of these, three patients fulﬁlled INSHI criteria for unmasking TB-associated IRIS (incidence rate of 1.6 per 100
person years). A body mass index of less than 18.5kg/m2 BMI (HR 5.85 95% CI 1.24–27.46, P = .025) and a C-reactive protein
greater than 5mg/L (HR 8.23 95% CI 1.36–38.33, P = .020) were risk factors for ART-associated TB at multivariate analysis. In
conclusion,with systematic TB screening (including culture and chest X-ray), the incidence of ART-associated TB is relatively low
in settings with high HIV and TB prevalence.
1.Introduction
Tuberculosis (TB) remains a leading cause of morbidity and
mortality in sub-Saharan Africa with the HIV pandemic
accounting for 31% of all new TB cases in adults [1, 2].
This is partly because available diagnostic tests are not
sensitive enough for early detection of all TB cases [3–5].
Additionally, patients often seek medical care late when they
already have advanced HIV disease or are very sick [6–8].
Sputumsmear microscopy, the tool forTB screening in most
resource-limited settings, has low sensitivity to diagnose TB
disease, especially in HIV-infected patients with advanced
immunodeﬁciency [9–11].
The World Health Organization (WHO) currently rec-
ommends routine screening for TB prior to antiretroviral
treatment (ART) initiation [12]. Such screening generally
targetssymptomatic patients.Therefore, TBpatientswithout
symptoms or with atypical symptoms and subclinicaldisease
are often not diagnosed. Intensive screening of HIV-infected
patients for TB prior to ART regardless of symptoms has
been demonstrated to increase the number of TB cases
identiﬁed [13, 14]. In a recent study from Durban, South2 Clinical and Developmental Immunology
Africa, TB was detected by intensive screening in 158 (19%)
of 825 patients undergoing ART preparation [13]. Only 52%
of these patients reported cough. It has been demonstrated
that patients with subclinical disease started on ART may
rapidly progress to symptomatic TB disease as a result of
immune reconstitution, and this risk is highest during the
ﬁrst three months of ART [15, 16].
Immune reconstitution inﬂammatory syndrome (IRIS)
is a disorder commonly observed upon ART initiation
in severely immune-compromised patients who have con-
comitant opportunistic infections. HIV/TB coinfection is
a leading cause of IRIS. Two clinical types of TB-
IRIS have been described: unmasking IRIS (an existing
occult/subclinical infection becomes clinically evident after
the start of ART) and paradoxical IRIS (worsening of a
successfully treated infection following the introduction
of ART) [17]. Whereas unmasking IRIS is postulated to
result from an imbalanced and exuberant inﬂammatory
response against a viable pathogenic organism in face of
a rapidly reconstituting immunity, in paradoxical TB-IRIS,
this dysregulated immune response is generally targeted
against residual pathogenic antigens. Exact mechanisms for
the dysfunctional restoration of pathogen-speciﬁc immune
responses are not well understood, but defects in antigen-
speciﬁc activated regulatory and eﬀectorCD4Tlymphocytes
have been suggested by a number of studies [18–21]. Several
studies have reported the incidence of paradoxical TB-IRIS,
but relatively few studies have reported the incidence of
unmasking and ART-associated TB-IRIS.
According to the International Network for the Study of
HIV-Associated IRIS (INSHI), ART-associated TB refers to
all TB diagnosed during ART, while the subset of patients
who develop rapidly progressive signs and symptoms of
TB, with exuberant inﬂammatory features, after initiation
of ART are called “unmasking TB-associated IRIS” [22]. In
programmes “rolling out” ART, ART-associated TB may be
diﬃcult to diﬀerentiate from multiple other opportunistic
pathologies, thus further delaying diagnosis and appropriate
treatment.
The purpose of thisstudy was to determine the incidence
and clinical manifestations of both ART-associated TB and
unmasking TB-associated IRIS in an ambulatory HIV care
setting in Uganda, where HIV prevalence is high [23]. A
secondary objective was to determine the predictive baseline
demographic, clinical, and laboratory parameters in patients
who develop ART-associated TB.
2.StudyMethodology
In a prospective cohort of HIV patients eligible for ART
at the Infectious Disease Institute (IDI), Kampala, Uganda,
we screened 247 patients for study entry. Inclusion criteria
were (1) age >18 years, (2) documented HIV infection,
(3) ART eligibility according to Uganda Ministry of Health
guidelines [24]( C D 4< 250 cells/μL), (4) ART na¨ ıve, (5) no
evidence of active TB disease by acid fast bacilli (AFB) smear
microscopy and chest radiograph (CXR) and (6) willingness
to participate in all followup visits and clinical examinations
and to have blood drawn for clinical and immunological
studies.
At study enrolment, the HIV serostatus was conﬁrmed
using a standard HIV testing algorithm [25], complete
blood count with diﬀerential CD4 count (FACSCalibur,
Becton Dickinson), and C-reactive protein (CRP) (COBAS
C-Reactive Protein (Latex), Roche Diagnostics; normal
range <5mg/L) were also measured. Patients were ini-
tiated on ART according to the Uganda National ART
guidelines [24]. TB screening was based on a standardized
symptom questionnaire (presence and duration of cough,
chest pain, fever, poor appetite, and weight loss; specifying
the duration of each symptom) and physical examination.
Patients who had a productive cough of greater than two
weeks had sputum collected for TB investigations. Two
expectoratedsputumsamples(earlymorning)wereobtained
and sent for microscopy by Ziehl Neelsen (ZN) stain and
Fluorescence microscopy (FM); and mycobacterial cultures
were performed at the national TB reference laboratory on
Lowenstein-Jensen (LJ) culture media. A sputum smear was
considered AFB positive if there were at least 10 bacilli per
100 ﬁelds. A positive mycobacterial culture was deﬁned as
any presence of Mycobacterium tuberculosis (M. tb) colonies
within a period of 6 to 8 weeks of incubation on LJ
media. A tuberculin skin test (TST) was administered by
intradermal injection of 2TU of RT23 in the volar aspect
of the left forearm, and all participants were instructed to
come back for its reading 48–72 hours later. A positive TST
was deﬁned as a skin induration of at least 5mm diameter.
All patients had CXRs done, and these were examined by
a radiologist and reported as normal (unlikely pulmonary
tuberculosis (PTB)), possible PTB (inﬁltrates, nodules, or
other abnormality), or probable PTB (with cavitation, ad-
enopathy, pleural eﬀusion, or miliary pattern). Patients
judged to have active TB (by clinical assessment, sputum
microscopy,orCXR)atARTcommencementwerestartedon
TB treatment and excluded from the study. Asymptomatic
participants with a positive TST and judged to be free of
TB based on CXR and sputum culture results were oﬀered
isoniazid prophylaxis.
Study participants were followed up and regularly
assessed for signs and symptoms suggestive of TB at 2,
4, 8, and 12 weeks after ART initiation, and quarterly
thereafter up to one year. Further TB investigations were
performed during followup if the patient developed new
or worsening symptoms suggestive of TB. This included
two sputum microscopy examinations for AFB and culture
on LJ media, a CXR (which was compared to one at
ART treatment start for evidence of worsening), and an
abdominal ultrasound. Patients diagnosed with TB were
started on TB treatment and censored from the study.
Further routine followup for TB treatment was conducted at
the national TB Leprosy programme clinic. The laboratory
examinations (haematology, immunology) were performed
at the Joint Clinical Research Centre (JCRC) and Makerere
University-John Hopkins University (MU-JHU) Core labo-
ratories in Kampala; microscopy examination for AFB and
mycobacterial cultures was performed at the National TB
Reference Laboratory in Kampala and JCRC TB laboratory.Clinical and Developmental Immunology 3
2.1. Study Deﬁnitions. TB was diagnosed by a study medical
oﬃcer according to WHO recommendations [26]. PTB
diagnosis was based on at least one sputum AFB-positive
result; a positive culture result or an abnormal CXR with a
clinical improvement after initiation of TB treatment. For
diagnosis of extrapulmonary TB, we considered one sample
from an extrapulmonary site which was AFBpositive orM.tb
culture positive, or histological or strong clinical evidence of
TB and decision to treat with a full course of TB treatment.
Patientswhodevelopedsignsandsymptoms suggestiveofTB
during followup were evaluated by the study medical oﬃcer
asTB-IRISsuspects usingastandardquestionnaireincluding
the INSHI TB-IRIS criteria. Two of the study investigators
(W. Worodria and R. Colebunders) later classiﬁed these
patients as ART-associated TB with or without unmasking
TB-IRISaccordingtotheINSHIcasedeﬁnitions(seeTable 1)
[22]. TB was deﬁned as prevalent if the participant had
signiﬁcant symptoms before the start of ART (a cough of
at least two weeks with or without chest pain, fever, or
poor appetite) with a positive AFB smear or M.tb culture,
or radiological abnormality with response to TB, treatment.
PatientswhohadnoneoftheabovefeaturesatARTinitiation
but developed them later during the course of treatment
were classiﬁed as incident TB. As ART-associated TB, we
includedall patientsdiagnosed withTBafterthestart ofART
regardless of the fact that after the start of ART a sputum
culture obtained before the start of ART was found to be
positive. We did not include ART-associated TB patients
diagnosed after the start of ART if retrospective review of
clinical ﬁles indicated that the diagnosis of TB was missed
according to WHO guidelines.
2.2. Data Management and Statistical Analysis. Patient data
was collected on case report forms, monitored by clinical
research associates, double entered, validated and stored
in an SQL database, and exported to STATA version 10.1
(STATA, College Station, TX, USA) for analysis. Baseline
characteristics for patients with prevalent TB, incident TB,
and without TB were compared. The predictive value of
clinical and laboratory parameters for any diagnosis of TB
and speciﬁcally for ART-associated TB was examined by Cox
proportionalhazards and reported ashazard ratios. The time
from start of ART to all diagnosis of TB and ART-associated
TB was represented as events on a Kaplan Meier curve. BMI
was categorized according to WHO recommendations with
underweight deﬁned as BMI < 18.5kg/m2 [27].
2.3. Ethics. Ethical approval for the study was obtained
from the Infectious Disease Scientiﬁc Review Committee,
MakerereFacultyofMedicineEthicsCommittee,theUganda
National Council on Science and Technology, and the
University of Antwerp Ethics Committee.
3.Results
Of 247 patients evaluated for ART eligibility, 225 were
enrolled, 17 were not eligible, and ﬁve were lost to followup
(Figure 1). The median age of study participants was 35.7
247 patients screened
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Figure 1: Study enrollment and retention.
years (interquartile range (IQR) 30.5–41.3 years) and 157
(70%) were females. The median CD4 count of the study
participants was 130 cells/μL (IQR 62–170),and 99 (44%) of
the patients were in WHO clinical stage 3 or 4 at enrolment.
Sixty eight (30%) of 220 patients had a positive tuberculin
skin test at enrolment. The median time from enrolment to
ARTinitiation was 10 days(IQR7–17).Nine (4.1%)patients
who initiated ART died, two patients withdrew consent, and
7 (3.2%) moved out of the study area. Six (2.7%) patients
were lost to followup and three were empirically started on
TB treatment. Five of the 9 patients who died had CD4
counts less than 50 cells/μL, and these 5 died with clinical
signs and symptoms suggestive of sepsis. One patient died of
gastroenteritis with severe dehydration; in one patient, the
cause of death was not established.
Of all patients screened for TB, 28 (13%) had cough
of greater than two weeks’ duration. Fifty (23%) patients
had at least one symptom (cough, chest pain, fever, poor
appetite, or weight loss) for greater than two weeks. Baseline
characteristics of patients diagnosed with prevalent TB,
incident TB, and without TB are presented in Table 2.O v e r
one year of followup, 14 (6%) patients were diagnosed with
TB after starting ART (incidence rate of 6.9 per 100 person
years). Of these, 6 (43%) had prevalent TB (2 had positive
TB cultures and 4 were sputum AFB smear negative but had
abnormalities on CXR) (Table 3). TB in these patients was4 Clinical and Developmental Immunology
Table 1: The International Network for the Study of HIV-Associated IRIS (INSHI) case deﬁnition for ART-associated tuberculosis [22].
ART-associated tuberculosis
(i) Patient is not receiving treatment for tuberculosis when ART is initiated.
(ii) Active tuberculosis is diagnosed after initiation of ART.
(iii) The diagnosis of tuberculosis should fulﬁl WHO criteria for smear-positive pulmonary tuberculosis, smear-negative
pulmonary tuberculosis, or extrapulmonary tuberculosis.
Unmasking tuberculosis-associated IRIS∗
(i) Patient is not receiving treatment for tuberculosis when ART is initiated and then presents with tuberculosis within 3 months
of starting ART.
And one of the following criteria must be met:
(ii) heightened intensity of clinical manifestations,particularly if there is evidence of a marked inﬂammatory component to the
presentation. Examples include tuberculosis lymphadenitis or tuberculosis abscesses with prominent acute inﬂammatory
features, presentation with tuberculosis that is complicated by respiratory failure due to adult respiratory distress syndrome, and
those who present with a marked systemic inﬂammatory syndrome related to tuberculosis,
(iii) once established on tuberculosis treatment, a clinical course that is complicated by a paradoxical reaction.
ART: antiretroviral therapy; IRIS: immune reconstitution inﬂammatory syndrome
∗Unmasking tuberculosis-associatedIRIS is a subsetof ART-associated tuberculosis.
0
0.02
P
r
o
p
o
r
t
i
o
n
w
i
t
h
T
B
d
i
a
g
n
o
s
e
d
0.04
0.06
0.08
0.1
0 60 120 180
Time to TB diagnosis (days)
240 300 360
Figure 2: Kaplan Meier curve of cumulative cases of tuberculosis
diagnosed among ART na¨ ıve patients with HIV infection starting
antiretroviral therapy.
unrecognized and therefore untreated priortoARTstart. The
remaining 8 (57%) were considered to be ART-associated
TB (incidence rate of 4.3 per 100 person years). Three of
these patients (patients 2, 6, and 7 in Table 4) had symptoms
consistent with unmasking TB-associated IRIS (incidence
rate of1.6 per 100 personyears). In 5 of8 patients with ART-
associated TB and in 2 out of 3 patients with unmasking
TB-associated IRIS, TB was diagnosed before an increment
in absolute CD4 counts (Table 4). Isoniazid prophylaxis was
provided to 23 (34%) of 68 eligible patients with normal
CXR and no evidence of TB. There were no complications
reported among patients on prophylaxis.
Participants diagnosed with TB had a lower BMI and
higher levels of CRP protein compared to patients without
TB. CRP greater than 5mg/L and BMI < 18.5kg/m2 were
predictive of ART-associated TB in uni- and multivariate
analysis (Table 5). When we included patients with unrec-
ognized TB as cases of ART-associated TB, the same factors
were also predictive (data not shown). The cumulative cases
of all patients diagnosed with TB are shown in Figure 2.
3.1. Description of a Patient to Illustrate Unmasking TB-Asso-
ciated IRIS. A 25-year-old HIV seropositive female (patient
2, Table 1) started ART (zidovudine/lamivudine/efavirenz)
with a CD4 count of 15cells/μL and viral load 128,056
copies/μL. At ART initiation, she complained of weight loss,
reduced appetite, and a skin rash since 2 weeks but had
no cough. Physical examination was normal; her BMI was
21.2kg/m2.C X Rw a sn o r m a l( Figure 3(a)), but CRP was
elevated to 92.21mg/L. Eleven weeks after starting ART, she
developed a productive cough with fever, drenching night
sweats, weight loss, and shortness of breath on exertion. On
examination, there was moderate abdominal distension due
to ascites. Sputum microscopy was AFB + on ﬂuorescence
microscopy. A repeat CXR demonstrated bilateral inﬁltrates
in all lung zones (Figure 3(b)). An abdominal ultrasound
conﬁrmed the ascites, but there were no abdominal lym-
phadenopathies. Sputum and ascitic ﬂuid cultures for M.tb
w e r ep o s i t i v e .A tT Bd i a g n o s i s ,t h eC D 4c o u n tw a s5c e l l s / μL
and her viral load <400 copies/μL. She fully recovered on
completion of TB treatment.
4.Discussion
Of 213 patients commencing ART, only 8 (3.8%) developed
ART-associated TB. This represents a lower incidence of
TB than reported in previous studies and may be due to
the systematic strategy used for TB screening: standardized
questionnaireforTB-relatedsymptoms,sputummicroscopy,
and culture, and CXR before commencement of ART. It
may also be caused by referral bias as patients with obvious
symptoms and signs of TB were not referred. Most previous
studies on ART-associated TB and unmasking TB-IRIS have
been retrospective [28–30], and few have been able to
systematically screen for TB using CXR prior to the start of
ART. This may have led to misclassiﬁcation of prevalent TBClinical and Developmental Immunology 5
Table 2: Baseline characteristics of 219 HIV-infected patients with prevalent TB, incident TB, and no TB.
Characteristics Prevalent TB (unrecognized) (n = 6) Incident TB (n = 8) No TB (n = 205)
Age (yrs), mean (SD) 38.5 (5.3) 38.3 (9.2) 36.4 (8.2)
Gender (Female) (%) 4 (67) 6 (75) 143 (70)
BMI (kg/m2), median (IQR) 18.8 (16.6–19.7)∗ 19.1 (17.9–21.2)∗∗ 22.8 (20.4–25.7)
CD4 counts (cell/μL), median (IQR) 131 (60–168) 103 (23–140) 131 (67–172)
Haemoglobin (g/dL), mean (SD) 11.9 (1.9) 10.5 (1.4)∗∗ 12.4 (1.9)
C-reactive protein (mg/dL), median (IQR) 24.9 (11.6–31.5)∗∗ 19.4 (3.9–51.3)∗ 2.2 (1.0–6.0)
TST positive at ART start (%) 4 (67) 1 (25) 59 (30)
ART: antiretroviral therapy; BMI, body mass index; IQR: interquartile range; SD: standard deviation; TB: tuberculosis; TST: tuberculin skin test.
P-values: ∗P<. 05, ∗∗P<. 001 compared with the no TB group.
Table 3: Characteristics of patients with prevalent (undiagnosed) TB.
Patient Age
(years)
Sex
Baseline
CD4 counts
(cells/μL)
Baseline clinical
symptoms∗
Baseline CXR
ﬁndings
Time to TB
diagnosis
(days)
TB category Basis of TB
diagnosis Outcomes
Patient 1 32 F 6
cough, chest
pain, weight
loss,poor
appetite
middle and lower
lung zone
inﬁltrates
24 PTB
culture+,
worsening
CXR
improved
Patient 2 43 M 168 no symptoms
upper and middle
lung zone
inﬁltrates with
cavitation
35 PTB worsening
CXR improved
Patient 3 35 F 121
cough, fever,
weight loss,
poor appetite
normal 65 PTB culture+ died
Patient 4 46 F 60
cough, chest
pain, poor
appetite
upper lung zone
inﬁltrates and left
side pleural
eﬀusion
0E P T B abnormal
CXR improved
Patient 5 35 F 140 cough
middle and lower
lung zone
inﬁltrates and
pleural thickening
43 PTB abnormal
CXR lost contact
Patient 6 41 M 180 no symptoms
middle and lower
lung zone
inﬁltrates and
bilateral cavities
10 PTB abnormal
CXR improved
Abbreviations: M: Male; F: Female; TB: tuberculosis; CXR: chest X-ray; PTB, pulmonary tuberculosis, AFB+: acid fast bacilli positive; AFB−: acid fast bacilli
negative; IRIS: immune reconstitution inﬂammatory syndrome.
∗Included only clinical symptomsof greater than two weeks.
disease and overdiagnosis of ART-associated TB.Evenin our
research cohort, there were 6 additional TB cases that were
not recognized at study enrolment. An earlier retrospective
study performed at the IDI clinic (prior to the INSHI
consensusdeﬁnition) found that26 (9.6%)of271ARTna¨ ıve
patients without a TB diagnosis at onset developed active
TB within one year of ART start [31]. Thirty-one percent of
these TB patients were diagnosed within 3 months of ART. A
morerecent studyattheIDIclinicfoundthatcentralnervous
system infections and mycobacterial disease were the main
causes of HIV-related mortality, especially in the ﬁrst three
months of ART [32]. Our data support systematic intensive
screening for TB that includes clinical evaluation, CXRs,
sputum microscopy, and culture [13, 14, 33]. Wide-scale
implementationofthisstrategy,however,requiresevaluation
of cost eﬀectiveness of the methods used and suﬃcient
resources at a programmatic level.
Only 3 patients in our study developed a clinical picture
that could be considered as unmasking TB-associated IRIS
according to the INSHI deﬁnition (see Table 1). A study
performed in South Africa did not ﬁnd any case of TB-
associated IRIS with an intensive pre-ART screening strategy
for TB [33] .I ti s ,h o w e v e r ,d i ﬃcult to deﬁne TB-associated
IRIS in the absence of a biological marker and because of
the subjectivity of quantifying the level of inﬂammatory
response.
ART-associated TB represents a heterogeneous group
of diseases that develop in the context of starting ART.6 Clinical and Developmental Immunology
Table 4: Characteristics of patients with ART-associated TB.
Patient Age
(years)
Sex CD4 counts Baseline
clinical
symptoms∗
Baseline
CXR
ﬁndings
Time to TB
(days) TB category Basis of TB
diagnosis
Basis of TB-
IRIS
diagnosis†
Outcomes
Base-
line
(cell/μL)
TB
(cell/μL)
Patient 1 53 F 156 148 weight loss Possible TB 345 TB pleura cytology NA Improved
Patient 2 27 F 15 5 weight loss,
anorexia Normal 79
Dissemin-
ated
TB
abnormal
CXR culture
+ve
2,4,5,6 Improved
Patient 3 31 F 90 68
cough, fever,
weight loss,
anorexia
Normal 14 PTB culture +ve NA Improved
Patient 4 37 M 123 — no symptoms Normal 24 PTB culture +ve NA Lost contact
Patient 5 42 M 116 95 cough, weight
loss, anorexia Possible TB 54 PTB culture +ve NA Died
Patient 6 45 F 21 28 weight loss Normal 17 PTB AFB+ 2,5,6,7 Improved
Patient 7 28 F 24 18 no symptoms Normal 20 TB adenitis FNA AFB+ 1,5,6 Lost contact
Patient 8 43 F 206 313 no symptoms Normal 100 PTB abnormal
CXR NA Improved
Abbreviations: M: Male; F: Female; TB: tuberculosis; CXR: chest X-ray; PTB: pulmonary tuberculosis; AFB+: acid fast bacilli positive; AFB−: acid fast bacilli
negative; IRIS: immune reconstitution inﬂammatory syndrome.
∗Included clinical symptomsof greater than two weeks.
†Criteria for TB-IRIS (new or worsening): 1: adenopathy; 2: CXR abnormalities; 3: central nervous system features of TB; 4: serositis; 5: constitutional
symptoms (fever, night sweats, weight loss); 6: respiratory symptoms (cough, dyspnea, stridor); 7: abdominal pain with peritonitis, hepatomegaly,
splenomegaly, or adenopathy; NA: not applicable.
Table 5: Cox proportional hazards for baseline predictors of ART-associated TB in HIV-infected patients commencing ART.
Baseline characteristics Unadjusted HR (95% CI) P-value Adjusted† HR (95% CI) P-value
Age (years)
>40 1.42 (0.26–7.77) .687 1.27 (0.21–7.80) .798
30–39 0.43 (0.06–3.05) .397 0.35 (0.05–2.64) .308
<30 1 1
Sex
Females 1.19 (0.24–5.88) .835 1.87 (0.34–10.21) .468
Males 1 1
Tuberculin skin test (TST)
positive 0.78 (0.16–3.88) .764 —
negative 1 —
C-reactive protein (mg/L)
≥5 8.23 (1.66–40.82) .010 7.23 (1.36–38.33) .020
<51 1
Haemoglobin (g/dL)
<12.5 6.66 (0.82–54.16) .076 2.31 (0.23–23.43) .477
≥12.5 1 1
CD4 cell counts (cells/μL)
<50 3.04 (0.72–12.74) .129 2.22 (0.49–10.16) .304
≥50 1 1
Body mass index (kg/m2)
<18.5 7.71 (1.92–30.89) .004 5.85 (1.24–27.46) .025
≥18.5 1 1
WHO clinical stage
3 and 4 4.68 (0.94–23.23) .065 1.82 (0.33–10.18) .495
1a n d2 1 1
†adjusted for age, sex, baseline C-reactive protein result, baseline haemoglobin, baseline CD4 counts, body mass index, and WHO clinical stage.
Abbreviations: ART: antiretroviral therapy; TB: tuberculosis; HR: hazard ratio.Clinical and Developmental Immunology 7
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Figure 3
One form is unmasking TB-associated IRIS which refers to
patients without clinical, microbiological, and radiological
evidence of TB at onset of ART who develop rapid and
exuberant features of inﬂammation within three months of
ART commencement. Another group are patients who were
symptomaticbeforethestart ofARTbutinwhomadiagnosis
of TB was missed due to lack of sensitive diagnostic tests.
Careful followup of such patients with regular evaluation
of their symptoms in addition to microbiological and
radiological tests may lead to early detection of TB. The
third category refers to patients with incident TB who were
asymptomatic at the onset of ART but develop signs and
symptoms of TB while on ART without the heightened signs
and symptoms of inﬂammation. This may be due to a new
infection or a reactivation of latent TB infection. Despite
some immunological recovery on ART, patients with HIV
infection still have an increased susceptibility to TB infection
or reinfection albeit with reduced risk [34].
At multivariate analysis, a raised CRP (5mg/L or
greater) and low BMI (<18.5kg/m2)w e r ep r e d i c t o r so f
ART-associated TB (Table 3). CRP is a nonspeciﬁc direct
quantitative measure of acute phase reaction [35, 36]. An
increment in the level of CRP is independent of the stage of
HIV infection and thus is useful for supporting a diagnosis
of opportunistic infections in HIV-coinfected patients. This
also makes it useful in monitoring TB treatment response
[37]. Low BMI is a marker for poor prognosis in patients
with HIV and has also been associated with increased risk
of TB and death [38, 39]. Early initiation of TB treatment in
HIV-infected patients with wasting and increased CRP levels
prior to initiating ART may therefore alleviate the excess
morbidity due to undiagnosed TB and ART-associated TB.
The mortality in this cohort of patients was minimal
(9(4%) of 219 patients starting ART) compared to other
reports. This could be due to the systematic screening and
close followup of patients in a study setting with early and
eﬀective TB treatment and ART. In particular, TB-IRIS was
not a signiﬁcant cause of early mortality in agreement with
retrospective cohort observations [32]. Several studies have
demonstrated a survival beneﬁt of early ART in HIV/TB-
coinfected patients. In the South African SAPIT trial, a 56%
reduction in mortality was observed in patients who started
ART during TB treatment compared to those who started
after completion of TB treatment [40]. More recently the
CAMELIA trial in Cambodia showed that the initiation
of ART 2 weeks after starting TB treatment signiﬁcantly
enhanced survival in TB/HIV-coinfected patients compared
to starting ART at 8 weeks [41]. This further emphasizes
the need to screen for TB prior to ART and to ensure early
treatment for both TB and HIV.
Our study has several limitations. Firstly, the sample
size was small. Secondly, 24 patients did not complete
the one year followup and 9 of them died. Postmortem
examinations were not performed, and therefore we possibly
underestimated the burden of TB. Thirdly, in the absence
of a biomarker for TB-IRIS, we relied only on clinical
evaluation which may be subjective in deﬁning patients with
exuberant inﬂammation. Patients with mild-to-moderate
degrees of inﬂammation were not considered as IRIS. In
spite of our eﬀorts to establish an accurate diagnosis of
TB, deﬁnite diagnosis (sputum smear positivity or culture-
positive results) could not be ascertained in 2 patients
(patient 1 and patient 8 in Table 4)c o n s i d e r e dt oh a v eA R T -
associated TB.With sputuminduction, bronchoscopy,liquid
culture, and/or molecular techniques, more patients with
subclinical TB may have been detected.
In conclusion, careful screening for TB before the start
of ART and the continuous assessment of patients for signs
and symptoms of TB after starting ART particularly among
patients that are wasted and have a raised CRP will lead to
an earlier TB diagnosis and ultimately to reduced morbidity
and mortality.8 Clinical and Developmental Immunology
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